Uniqure NV

QURE · NASDAQ

$22.72+$0.515 (+2.32%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $22.20

Latest news

Press releaseOct 6, 6:00 PM ETBusiness Wire
UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share Drop
NewsSep 30, 9:55 AM ETAvi Kapoor
Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday
Press releaseSep 29, 8:12 PM ETPRNewswire
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)
Press releaseSep 29, 1:28 PM ETBusiness Wire
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law
NewsSep 29, 12:01 PM ETAvi Kapoor
Crude Oil Down 1%; US Job Openings Fall In August
Press releaseSep 29, 11:00 AM ETGlobe Newswire
QURE Investor Alert: uniQure Securities Investigation - Kehoe Law Firm, P.C.
NewsSep 29, 10:28 AM ETVandana Singh
Why Is uniQure Stock Sinking on Tuesday?
NewsSep 29, 10:13 AM ETAvi Kapoor
Dow Tumbles 100 Points; Carnival Posts Upbeat Q3 Earnings
NewsSep 29, 7:16 AM ET
uniQure Announces Additional Data From Ongoing Phase I/II Studies Of Ifezuntirgene Inilparvovec For Treatment Of Huntington’s Disease; In 12 High-Dose Patients At 48 Months, Both cUHDRS And TFC Continued To Demonstrate Meaningful Slowing Of Disease Progression And Clear Dose-Dependent Response; Primary Endpoint Of cUHDRS Showed 44% Slowing Of Disease Progression
Press releaseSep 29, 7:12 AM ETGlobe Newswire
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression
NewsSep 2, 2:23 PM ETVandana Singh
uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says
NewsSep 2, 7:10 AM ET
uniQure Submits Biologics License Application to FDA for Accelerated Approval of Ifezuntirgene Inilparvovec (AMT-130), Gene Therapy for Huntington’s Disease
Press releaseSep 2, 7:05 AM ETGlobe Newswire
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease
NewsAug 14, 1:35 PM ET
9 Health Care Stocks Whale Activity In Today’s Session
NewsJul 30, 5:05 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseJul 29, 7:05 AM ETGlobe Newswire
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
NewsJun 26, 2:06 PM ETVandana Singh
What's Going On With Capricor Therapeutics Stock On Friday?
Press releaseJun 25, 4:10 PM ETGlobe Newswire
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
Press releaseJun 23, 9:13 PM ETGlobe Newswire
uniQure Announces Pricing of Upsized $225 Million Public Offering
NewsJun 22, 11:51 AM ETVandana Singh
uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy
NewsJun 22, 9:23 AM ETVandana Singh
Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy
Press releaseJun 19, 7:05 AM ETGlobe Newswire
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
NewsJun 18, 6:27 PM ETTimur Mekhantev
uniQure Soars After FDA's U-Turn Opens Accelerated Approval Pathway for Huntington's Therapy
NewsJun 17, 12:06 PM ETAvi Kapoor
Crude Oil Edges Higher; US Retail Sales Top Estimates
Press releaseJun 17, 10:37 AM ETGlobe Newswire
Biotech's New Frontier: Companies Breaking Through Medicine's Toughest Barriers
NewsJun 17, 10:31 AM ETVandana Singh
FDA Signals uniQure Huntington Gene Therapy Data Could Back Accelerated Approval
NewsJun 17, 10:11 AM ETAvi Kapoor
Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday
NewsJun 4, 2:04 PM ET
Watching uniQure; Shares See A Spike In Volume, Endpoints News Reports "Acting FDA Commissioner Pledges To Prevent Political Interference In Rare Disease Meeting"
NewsMay 11, 12:17 PM ET
'Trump Approves Plan To Fire FDA Commissioner Marty Makary, Sources Say' - CBS
NewsMay 5, 1:44 PM ETVandana Singh
What's Going On With Replimune Stock On Tuesday?
NewsMay 5, 9:40 AM ET
Transcript: uniQure Q1 2026 Earnings Conference Call
NewsMay 5, 7:12 AM ET
Earnings Scheduled For May 5, 2026
Press releaseMay 5, 7:05 AM ETGlobe Newswire
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates
NewsApr 30, 8:06 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Press releaseApr 28, 7:05 AM ETGlobe Newswire
uniQure to Announce First Quarter 2026 Financial Results
Press releaseApr 13, 12:58 PM ETBusiness Wire
QURE CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
Press releaseApr 10, 3:43 PM ETBusiness Wire
uniQure N.V. 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against uniQure N.V. - QURE
Press releaseApr 10, 1:15 PM ETBusiness Wire
QURE Deadline: Rosen Law Firm Urges uniQure N.V. (NASDAQ: QURE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Press releaseApr 10, 11:34 AM ETPRNewswire
QURE UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
Press releaseApr 10, 11:01 AM ETGlobe Newswire
UNIQURE DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders with Large Losses to Contact the Firm Before April 13th
Press releaseApr 9, 12:26 PM ETPRNewswire
QURE 4-DAY DEADLINE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data
Press releaseApr 9, 11:54 AM ETGlobe Newswire
uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE
Press releaseApr 8, 4:57 PM ETGlobe Newswire
INVESTOR DEADLINE: uniQure (QURE) Investors with Substantial Losses Have Opportunity to Lead the uniQure Class Action Lawsuit– Hagens Berman
NewsMar 2, 10:17 AM ETAvi Kapoor
Dow Falls 150 Points; ISM Manufacturing PMI Edges Lower In February
NewsJan 9, 1:14 PM ETEvette Mitkov
uniQure Stock Jumps After Scheduling FDA Type A Meeting For AMT‑130 Approval Pathway
NewsDec 17, 10:07 AM ETAvi Kapoor
Toro, DBV Technologies, Udemy, ABM Industries And Other Big Stocks Moving Higher On Wednesday
NewsDec 11, 9:08 AM ETAvi Kapoor
Roku To Rally More Than 28%? Here Are 10 Top Analyst Forecasts For Thursday
NewsNov 3, 8:14 AM ETAvi Kapoor
Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session
NewsOct 6, 8:48 AM ETAvi Kapoor
Cramer Warns On One Chip Stock, Says Broadcom Is The Better Bet

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share Drop

Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)

QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law

Crude Oil Down 1%; US Job Openings Fall In August

QURE Investor Alert: uniQure Securities Investigation - Kehoe Law Firm, P.C.

Why Is uniQure Stock Sinking on Tuesday?

Dow Tumbles 100 Points; Carnival Posts Upbeat Q3 Earnings

uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression

uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says

uniQure Submits Biologics License Application to FDA for Accelerated Approval of Ifezuntirgene Inilparvovec (AMT-130), Gene Therapy for Huntington’s Disease

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease

9 Health Care Stocks Whale Activity In Today’s Session

12 Health Care Stocks Moving In Thursday's After-Market Session

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

What's Going On With Capricor Therapeutics Stock On Friday?

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

uniQure Announces Pricing of Upsized $225 Million Public Offering

uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy

Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

uniQure Soars After FDA's U-Turn Opens Accelerated Approval Pathway for Huntington's Therapy

Crude Oil Edges Higher; US Retail Sales Top Estimates

Biotech's New Frontier: Companies Breaking Through Medicine's Toughest Barriers

FDA Signals uniQure Huntington Gene Therapy Data Could Back Accelerated Approval

Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday

Watching uniQure; Shares See A Spike In Volume, Endpoints News Reports "Acting FDA Commissioner Pledges To Prevent Political Interference In Rare Disease Meeting"

'Trump Approves Plan To Fire FDA Commissioner Marty Makary, Sources Say' - CBS

What's Going On With Replimune Stock On Tuesday?

Transcript: uniQure Q1 2026 Earnings Conference Call

Earnings Scheduled For May 5, 2026

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

12 Health Care Stocks Moving In Thursday's Pre-Market Session

uniQure to Announce First Quarter 2026 Financial Results

QURE CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

uniQure N.V. 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against uniQure N.V. - QURE

QURE Deadline: Rosen Law Firm Urges uniQure N.V. (NASDAQ: QURE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

QURE UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

UNIQURE DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders with Large Losses to Contact the Firm Before April 13th

QURE 4-DAY DEADLINE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data

uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE

INVESTOR DEADLINE: uniQure (QURE) Investors with Substantial Losses Have Opportunity to Lead the uniQure Class Action Lawsuit– Hagens Berman

Dow Falls 150 Points; ISM Manufacturing PMI Edges Lower In February

uniQure Stock Jumps After Scheduling FDA Type A Meeting For AMT‑130 Approval Pathway

Toro, DBV Technologies, Udemy, ABM Industries And Other Big Stocks Moving Higher On Wednesday

Roku To Rally More Than 28%? Here Are 10 Top Analyst Forecasts For Thursday

Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Cramer Warns On One Chip Stock, Says Broadcom Is The Better Bet